Analysis of treatment benefits and prognostic factors for posttransplant HCC recurrence in a large Euro-American-Asian cohort

医学 内科学 肝细胞癌 比例危险模型 倾向得分匹配 回顾性队列研究 危险系数 队列 生存分析 肝移植 多元分析 置信区间 肿瘤科 外科 胃肠病学 移植
作者
Zhihao Li,I. Chen,Leonardo Centonze,Christian Tibor Josef Magyar,Woo Jin Choi,Sachin Shah,Grainne M. O’Kane,Arndt Vogel,Luciano De Carlis,Jan Lerut,Quirino Lai,Neil Mehta,Chao‐Long Chen,Gonzalo Sapisochín
出处
期刊:Liver Transplantation [Lippincott Williams & Wilkins]
卷期号:31 (4): 450-463 被引量:3
标识
DOI:10.1097/lvt.0000000000000501
摘要

Posttransplant HCC recurrence significantly impacts survival, yet its management is challenging due to limited evidence. With recent advancements in HCC treatment, updated data on managing recurrent diseases are needed. In this retrospective study across 6 centers (2000-2022), we employed Cox proportional-hazards regression and log-rank tests to assess survival differences. A prognostic score model was developed to categorize patient survival. The efficacy of tyrosine kinase inhibitors was evaluated through propensity score matching. In our study, 431 of 3349 (14%) patients with HCC who underwent transplantation developed recurrence within a median interval of 18 (IQR: 9-32) months. One hundred forty-seven (34%) underwent curative-intent treatments, 207 (48%) received palliative treatments, and 77 (18%) were given best-supportive care. Patients undergoing curative-intent treatments had better survival from the time of recurrence with a median survival of 45 (95% CI: 36-63) months and 1/3/5-year survival of 90%/56%/43% compared to those receiving noncurative treatments (median: 11 [95% CI: 10-13] mo, 1/3/5-y survival of 46%/10%/7%, log-rank p < 0.001). Patients with recurrence diagnosed in the era 2018-2022 showed improved survival over the previous era (HR 0.64 [95% CI: 0.47-0.86]). Multivariable analysis identified 5 prognostic factors: ineligibility for curative-intent treatment (HR: 3.5 [95% CI: 2.7-4.6]), recurrence within 1 year (HR: 1.7 [95% CI: 1.3-2.1]), poor tumor differentiation (HR: 1.5 [95% CI: 1.1-1.9]), RETREAT score ≥3 (HR: 1.4 [95% CI: 1.1-1.8]), and alpha-fetoprotein at recurrence ≥400 ng/mL (HR: 1.4 [95% CI: 1.1-1.9]). These factors contributed to a prognostic scoring system (0-9) that stratified patients into 3 prognosis groups. Both propensity score-matched analysis and multivariable regression indicated that lenvatinib was not statistically superior to sorafenib in terms of efficacy. Curative-intent treatments should be advocated for patients with posttransplant recurrence whenever possible. Prognostic factors linked to aggressive tumor biology significantly influence survival. Advancements in HCC management have improved survival outcomes over the past 5 years.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
上官若男的应助被宁灭龙采纳,获得10
刚刚
刚刚
lee完成签到,获得积分10
1秒前
aidenchen完成签到,获得积分10
1秒前
1秒前
1秒前
王珏完成签到,获得积分10
2秒前
3秒前
深情安青的应助被小白采纳,获得10
3秒前
CaliU发布了新的文献求助10
3秒前
搜集达人的应助被Daangxi采纳,获得10
3秒前
lk发布了新的文献求助10
4秒前
所所的应助被困就睡觉采纳,获得10
4秒前
lyhh完成签到,获得积分10
4秒前
4秒前
英姑的应助被忧郁的鱿鱼采纳,获得10
4秒前
风趣的鼠标完成签到,获得积分10
5秒前
Color完成签到,获得积分10
5秒前
甜甜发布了新的文献求助10
5秒前
FashionBoy的应助被yy采纳,获得10
6秒前
墨辞完成签到,获得积分10
6秒前
6秒前
6秒前
6秒前
可爱觅松发布了新的文献求助10
6秒前
6秒前
田様的应助被明理鸿采纳,获得10
6秒前
秋风的应助被wyk采纳,获得10
6秒前
杀出个黎明举报求助违规成功
7秒前
Anonymous举报求助违规成功
7秒前
MchemG举报求助违规成功
7秒前
Ren的应助被朋友需要采纳,获得200
7秒前
脑洞疼的应助被lulululu采纳,获得10
7秒前
扶风阁主发布了新的文献求助10
7秒前
8秒前
七听的应助被番茄采纳,获得30
8秒前
8秒前
8秒前
ECCE发布了新的文献求助10
9秒前
mjq发布了新的文献求助10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8155737
求助须知:如何正确求助?哪些是违规求助? 9552018
关于积分的说明 21707687
捐赠科研通 7744923
什么是DOI,文献DOI怎么找? 3426177
关于科研通互助平台的介绍 2551229
邀请新用户注册赠送积分活动 2469949